CARGO Therapeutics, Inc. (NASDAQ:CRGX – Get Free Report)’s stock price was down 3.2% during mid-day trading on Wednesday . The stock traded as low as $19.13 and last traded at $19.37. Approximately 25,864 shares changed hands during trading, a decline of 91% from the average daily volume of 277,271 shares. The stock had previously closed at $20.00.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group increased their price target on CARGO Therapeutics from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, March 22nd.
Get Our Latest Stock Report on CARGO Therapeutics
CARGO Therapeutics Stock Performance
CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) last issued its earnings results on Thursday, March 21st. The company reported ($1.49) EPS for the quarter, topping analysts’ consensus estimates of ($1.62) by $0.13. On average, analysts predict that CARGO Therapeutics, Inc. will post -5.6 earnings per share for the current year.
Institutional Investors Weigh In On CARGO Therapeutics
Several hedge funds have recently made changes to their positions in CRGX. Legal & General Group Plc bought a new stake in shares of CARGO Therapeutics in the fourth quarter valued at about $232,000. Goldman Sachs Group Inc. purchased a new position in CARGO Therapeutics during the 4th quarter valued at about $287,000. Northern Trust Corp purchased a new stake in shares of CARGO Therapeutics in the 4th quarter worth approximately $877,000. Norges Bank bought a new position in shares of CARGO Therapeutics during the fourth quarter valued at approximately $1,130,000. Finally, Sphera Funds Management LTD. purchased a new position in CARGO Therapeutics during the fourth quarter valued at approximately $1,736,000. 93.16% of the stock is currently owned by hedge funds and other institutional investors.
About CARGO Therapeutics
CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients in the Unites States. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate, which is in phase 2 trails, designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
Featured Articles
- Five stocks we like better than CARGO Therapeutics
- Industrial Products Stocks Investing
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
- How to Start Investing in Real Estate
- Abbott Laboratories Outlook is Healthy: Buy the Dip
- What is a buyback in stocks? A comprehensive guide for investors
- ASML Fires Warning Shot For Tech Investors
Receive News & Ratings for CARGO Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CARGO Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.